Home LiteratureArticle Details

PMID: 18184971 Published · ppublish English Letter Research Support, Non-U.S. Gov't

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.

The New England journal of medicine ·Vol. 358 ·No. 2 ·2008-01-10 ·Pages 200-3

Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR

Abstract

暂无摘要

MeSH Terms

Angiomyolipoma/drug therapy,etiology Clinical Trials, Phase II as Topic Humans Immunosuppressive Agents/adverse effects,therapeutic use Kidney Diseases/drug therapy,etiology Lymphangioleiomyomatosis/complications Protein Kinase Inhibitors/therapeutic use Protein Kinases/metabolism Sirolimus/adverse effects,therapeutic use TOR Serine-Threonine Kinases Tuberous Sclerosis/complications

Chemicals

Immunosuppressive Agents Protein Kinase Inhibitors Protein Kinases MTOR protein, human TOR Serine-Threonine Kinases Sirolimus

Authors & Affiliations

11 authors, click to expand affiliations / ORCID

Davies D Mark

Johnson Simon R

Tattersfield Anne E

Kingswood J Chris

Cox Jane A

McCartney Deborah L

Doyle Tim

Elmslie Frances

Saggar Anand

de Vries Petrus J

Sampson Julian R

Article Info

Journal

The New England journal of medicine

Abbr.

N Engl J Med

ISSN

1533-4406

DOI

10.1056/NEJMc072500

Published

2008-01-10

Pages

200-3

Language

English

Region

United States

NLM ID

0255562

Subset

Grants

Medical Research Council · G0301154 · United Kingdom

Corrections

CommentIn

PMID: 18450609

External Links

PubMed source DOI: 10.1056/NEJMc072500 View journal details

Analysis Services

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.

Contact

WeChat Official Account